Climb Bio (CLYM) Operating Income (2020 - 2026)

Climb Bio has reported Operating Income for 7 years, with the latest figure at -$15.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 33.92% year-over-year to -$15.2 million; the trailing twelve-month figure through Mar 2026 stood at -$60.1 million (up 41.12% YoY), and the FY2025 full-year result was -$67.9 million, up 17.24% from the prior year.
• Operating Income for Q1 2026 stood at -$15.2 million, up from -$19.3 million in the prior quarter.
• The five-year high for Operating Income was -$3.0 million in Q1 2024, with the low at -$56.4 million in Q2 2024.
• Historically, Operating Income has averaged -$14.7 million across 5 years, with a median of -$11.7 million in 2024.
• The largest YoY upside for Operating Income was 87.18% in 2024 against a maximum downside of 739.62% in 2024.
• Climb Bio's Operating Income stood at -$9.6 million in 2022, then surged by 46.39% to -$5.1 million in 2023, then tumbled by 113.02% to -$10.9 million in 2024, then slumped by 76.85% to -$19.3 million in 2025, then climbed by 21.17% to -$15.2 million in 2026.
• The last three Operating Income figures came in at -$15.2 million (Q1 2026), -$19.3 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.